Achieving red-light anticancer photodynamic therapy under hypoxia using Ir(iii)–COUPY conjugates
Open Access
- 4 March 2025
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in Inorganic Chemistry Frontiers
- Vol. 12 (9) , 3367-3383
Abstract
Despite the potential of photodynamic therapy (PDT), this oxygen-dependent oncological treatment is greatly restricted in the clinic by the well-known hypoxic feature of solid tumors. Here we provide new insights on the development of PDT agents based on conjugates between COUPY fluorophores and cyclometalated iridium(III) complexes with the aim of overcoming this limitation. The structural modifications carried out within the metal core of Ir(III)-COUPY conjugates, based on the incorporation of trifluorobenzyl groups at the cyclometalating ligands, allowed efficient explotation of Type I PDT mechanisms while retaining operativity at long-wavelength visible light, which facilitates deeper tissue penetration compared with short wavelengths. Photobiological evaluation revealed that Ir(III)‑COUPY conjugate 3c achieved potent photocytotoxicity towards cisplatin-resistant ovarian (A2780cis) and mammary (EO771) cancer cell lines, efficiently photogenerated Type I and Type II ROS and photoinduced apoptotic cell death using red light irradiation (620 nm). Importantly, this Ir(III)-COUPY conjugate retained such potent photoactivity under low-oxygen environment conditions (2% O2), delivering equipotent photocytotoxicity towards normoxic and hypoxic adherent cancer cells. Compound 3c was found highly phototoxic against EO771 multicellular tumor spheroids and showed no signs of toxicity or adverse effects in mice, which could facilitate in vivo phototherapeutic applications. Taken together, this study demonstrated that the conjugation between COUPY dyes and rationally-designed Ir(III) complexes represents a frontier strategy for the development of new red light‑activated photosensitizers capable of operating under hypoxia, holding promise to achieve satisfactory anticancer PDT effects.Keywords
Funding Information
- Fundación Séneca (21989/PI/22)
- Generalitat Valenciana (CIAICO/2022/121)
- Universitat de Barcelona
- Generalitat de Catalunya (2017 FI_B_00617, 2018 FI_B1 00174, 2019 FI_B2 00167)
- Agència de Gestió d'Ajuts Universitaris i de Recerca (2021 SGR 01023)
- Ministero dell'Università e della Ricerca (2022AN47CA, H53D23003820001, DD 862, 16/06/2023)
- European Regional Development Fund (PID2023-146161OB-I00, PID2021-122850NB-I00, PID2021-127554NA-I00)
- Ministerio de Ciencia, Innovación y Universidades (PID2020-117508RB-I00, PID2020-115801RB-C22, JDC2023-050936-I, PID2021-122850NB-I00, PID2021-127554NA-I00, PID2023-146161OB-I00)
- Institució Catalana de Recerca i Estudis Avançats (Ac2232308)
This publication has 62 references indexed in Scilit:
- Asymmetric Redox Allylic Alkylation to Access 3,3′‐Disubstituted Oxindoles Enabled by Ni/NHC Cooperative CatalysisAngewandte Chemie International Edition, 2022
- BODIPY‐Based Photodynamic Agents for Exclusively Generating Superoxide Radical over Singlet OxygenAngewandte Chemie International Edition, 2021
- A Cyclometalated IrIII Complex Conjugated to a Coumarin Derivative Is a Potent Photodynamic Agent against Prostate Differentiated and Tumorigenic Cancer Stem CellsChemistry – A European Journal, 2021
- In‐vitro and In‐vivo Photocatalytic Cancer Therapy with Biocompatible Iridium(III) PhotocatalystsAngewandte Chemie, 2021
- In‐vitro and In‐vivo Photocatalytic Cancer Therapy with Biocompatible Iridium(III) PhotocatalystsAngewandte Chemie International Edition, 2021
- Evaluation of a Ruthenium coordination complex as photosensitizer for PDT of bladder cancer: Cellular response, tissue selectivity and in vivo responseTranslational Biophotonics, 2020
- New Designs for Phototherapeutic Transition Metal ComplexesAngewandte Chemie International Edition, 2019
- Towards Novel Photodynamic Anticancer Agents Generating Superoxide Anion Radicals: A Cyclometalated IrIIIComplex Conjugated to a Far‐Red Emitting CoumarinAngewandte Chemie International Edition, 2019
- Half‐sandwich Iridium(III) Benzimidazole‐Appended Imidazolium‐Based N‐heterocyclic Carbene Complexes and Antitumor ApplicationChemistry – An Asian Journal, 2018
- Exploring the Effect of Polypyridyl Ligands on the Anticancer Activity of Phosphorescent Iridium(III) Complexes: From Proteosynthesis Inhibitors to Photodynamic Therapy AgentsChemistry – A European Journal, 2018